First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
First Tracks Biotherapeutics reported its first quarter 2026 financial results following its April 20th launch with a $180 million cash runway. The company is advancing its antibody therapeutics portfolio focusing on ANB033, a CD122 antagonist in Phase 1b trials for celiac disease and eosinophilic esophagitis, with top-line data expected by late 20…